• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有广泛化学覆盖范围的克鲁兹蛋白酶抑制剂预测性全局模型。

Predictive Global Models of Cruzain Inhibitors with Large Chemical Coverage.

作者信息

Rosas-Jimenez Jose Guadalupe, Garcia-Revilla Marco A, Madariaga-Mazon Abraham, Martinez-Mayorga Karina

机构信息

Division de Ciencias Naturales y Exactas, Universidad de Guanajuato, Guanajuato 36050, Mexico.

Instituto de Quimica, Universidad Nacional Autonoma de Mexico, Mexico City 04510, Mexico.

出版信息

ACS Omega. 2021 Mar 5;6(10):6722-6735. doi: 10.1021/acsomega.0c05645. eCollection 2021 Mar 16.

DOI:10.1021/acsomega.0c05645
PMID:33748586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7970485/
Abstract

Chagas disease affects 8-11 million people worldwide, most of them living in Latin America. Moreover, migratory phenomena have spread the infection beyond endemic areas. Efforts for the development of new pharmacological therapies are paramount as the pharmacological profile of the two marketed drugs currently available, nifurtimox and benznidazole, needs to be improved. Cruzain, a parasitic cysteine protease, is one of the most attractive biological targets due to its roles in parasite survival and immune evasion. In this work, we compiled and curated a database of diverse cruzain inhibitors previously reported in the literature. From this data set, quantitative structure-activity relationship (QSAR) models for the prediction of their pIC values were generated using -nearest neighbors and random forest algorithms. Local and global models were calculated and compared. The statistical parameters for internal and external validation indicate a significant predictability, with values around 0.66 and 0.61 and external coefficients of 0.725 and 0.766. The applicability domain is quantitatively defined, according to QSAR good practices, using the leverage and similarity methods. The models described in this work are readily available in a Python script for the discovery of novel cruzain inhibitors.

摘要

恰加斯病影响着全球800万至1100万人,其中大多数生活在拉丁美洲。此外,人口迁移现象已使感染扩散到了流行地区之外。由于目前市面上的两种药物硝呋莫司和苯硝唑的药理特性需要改进,开发新的药物疗法至关重要。克鲁斯蛋白酶是一种寄生性半胱氨酸蛋白酶,因其在寄生虫存活和免疫逃避中的作用,成为最具吸引力的生物学靶点之一。在这项工作中,我们整理并建立了一个文献中先前报道的多种克鲁斯蛋白酶抑制剂的数据库。利用k近邻和随机森林算法,从该数据集中生成了预测其pIC值的定量构效关系(QSAR)模型。计算并比较了局部和全局模型。内部和外部验证的统计参数表明具有显著的可预测性,内部R²值约为0.66和0.61,外部R²系数为0.725和0.766。根据QSAR的良好实践,使用杠杆率和相似性方法对适用域进行了定量定义。这项工作中描述的模型可在一个Python脚本中轻松获取,用于发现新型克鲁斯蛋白酶抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/31376290f5da/ao0c05645_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/2033c68175ba/ao0c05645_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/ae9945d1166a/ao0c05645_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/16ca99b06b28/ao0c05645_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/e8eb50892f43/ao0c05645_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/3f9e6b01c50c/ao0c05645_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/a854d94a3b99/ao0c05645_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/50c801909666/ao0c05645_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/b4b5607306e7/ao0c05645_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/f62ca4e9a2b2/ao0c05645_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/5b51156501b5/ao0c05645_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/63b8ff3c0610/ao0c05645_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/31376290f5da/ao0c05645_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/2033c68175ba/ao0c05645_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/ae9945d1166a/ao0c05645_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/16ca99b06b28/ao0c05645_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/e8eb50892f43/ao0c05645_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/3f9e6b01c50c/ao0c05645_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/a854d94a3b99/ao0c05645_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/50c801909666/ao0c05645_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/b4b5607306e7/ao0c05645_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/f62ca4e9a2b2/ao0c05645_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/5b51156501b5/ao0c05645_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/63b8ff3c0610/ao0c05645_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/7970485/31376290f5da/ao0c05645_0013.jpg

相似文献

1
Predictive Global Models of Cruzain Inhibitors with Large Chemical Coverage.具有广泛化学覆盖范围的克鲁兹蛋白酶抑制剂预测性全局模型。
ACS Omega. 2021 Mar 5;6(10):6722-6735. doi: 10.1021/acsomega.0c05645. eCollection 2021 Mar 16.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors.一系列作为克鲁兹蛋白酶抑制剂的苯并咪唑衍生物的分子建模与构效关系
Future Med Chem. 2017 May;9(7):641-657. doi: 10.4155/fmc-2016-0236. Epub 2017 May 16.
4
Structure-Based and Molecular Modeling Studies for the Discovery of Cyclic Imides as Reversible Cruzain Inhibitors With Potent Anti- Activity.基于结构和分子建模研究发现环状酰亚胺作为具有强效抗活性的可逆克鲁蛋白酶抑制剂。
Front Chem. 2019 Nov 25;7:798. doi: 10.3389/fchem.2019.00798. eCollection 2019.
5
Convergent QSAR Models for the Prediction of Cruzain Inhibitors.用于预测克鲁兹蛋白酶抑制剂的收敛性定量构效关系模型
ACS Omega. 2023 Oct 13;8(42):38961-38982. doi: 10.1021/acsomega.3c03376. eCollection 2023 Oct 24.
6
Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from Trypanosoma cruzi.一类克氏锥虫主要半胱氨酸蛋白酶选择性抑制剂的构效关系
J Enzyme Inhib Med Chem. 2008 Dec;23(6):964-73. doi: 10.1080/14756360701810322.
7
Antiprotozoal QSAR modelling for trypanosomiasis (Chagas disease) based on thiosemicarbazone and thiazole derivatives.基于缩氨基硫脲和噻唑衍生物的锥虫病(恰加斯病)抗寄生虫定量构效关系建模。
J Mol Graph Model. 2021 Mar;103:107821. doi: 10.1016/j.jmgm.2020.107821. Epub 2020 Dec 7.
8
Development of a pharmacophore for cruzain using oxadiazoles as virtual molecular probes: quantitative structure-activity relationship studies.以恶二唑作为虚拟分子探针开发克鲁萨因药效团:定量构效关系研究
J Comput Aided Mol Des. 2017 Sep;31(9):801-816. doi: 10.1007/s10822-017-0039-0. Epub 2017 Aug 9.
9
Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.克氏锥虫克鲁兹蛋白酶系列抑制剂的定量构效关系:分子建模、比较分子力场分析和比较分子相似性指数分析研究
J Mol Graph Model. 2009 Aug;28(1):3-11. doi: 10.1016/j.jmgm.2009.03.001. Epub 2009 Mar 14.
10
Highly predictive hologram QSAR models of nitrile-containing cruzain inhibitors.含腈基的克沙尔蛋白酶抑制剂的高预测性全息定量构效关系模型
J Biomol Struct Dyn. 2017 Nov;35(15):3232-3249. doi: 10.1080/07391102.2016.1252282. Epub 2016 Nov 28.

引用本文的文献

1
TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease.TrypPROTACs:为恰加斯病解锁新的治疗策略
Pharmaceuticals (Basel). 2025 Jun 19;18(6):919. doi: 10.3390/ph18060919.
2
The pursuit of accurate predictive models of the bioactivity of small molecules.对小分子生物活性精确预测模型的追求。
Chem Sci. 2024 Jan 12;15(6):1938-1952. doi: 10.1039/d3sc05534e. eCollection 2024 Feb 7.
3
Convergent QSAR Models for the Prediction of Cruzain Inhibitors.用于预测克鲁兹蛋白酶抑制剂的收敛性定量构效关系模型

本文引用的文献

1
Update on relevant trypanosome peptidases: Validated targets and future challenges.关于相关锥虫肽酶的最新研究进展:已验证的靶标和未来的挑战。
Biochim Biophys Acta Proteins Proteom. 2021 Feb;1869(2):140577. doi: 10.1016/j.bbapap.2020.140577. Epub 2020 Nov 30.
2
Synthesis and biological evaluation in vitro and in silico of N-propionyl-N'-benzeneacylhydrazone derivatives as cruzain inhibitors of Trypanosoma cruzi.N-丙酰基-N'-苯甲酰腙衍生物的合成及其对 Trypanosoma cruzi 半胱氨酸蛋白酶 cruzain 的体外和计算机模拟生物评价。
Mol Divers. 2022 Feb;26(1):39-50. doi: 10.1007/s11030-020-10156-5. Epub 2020 Nov 20.
3
ACS Omega. 2023 Oct 13;8(42):38961-38982. doi: 10.1021/acsomega.3c03376. eCollection 2023 Oct 24.
4
Targeting Cysteine Proteases and their Inhibitors to Combat Trypanosomiasis.靶向半胱氨酸蛋白酶及其抑制剂以对抗锥虫病。
Curr Med Chem. 2024;31(16):2135-2169. doi: 10.2174/0929867330666230619160509.
5
Computational approaches towards the discovery and optimisation of cruzain inhibitors.计算方法在克氏锥虫氨酸抑制剂的发现和优化中的应用。
Mem Inst Oswaldo Cruz. 2022 Mar 16;117:e210385. doi: 10.1590/0074-02760210385. eCollection 2022.
6
Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors.作为克氏锥虫抑制剂的一系列咪唑类化合物的 chemoinformatics 研究。
Biomolecules. 2021 Apr 15;11(4):579. doi: 10.3390/biom11040579.
The role of imidazole and benzimidazole heterocycles in Chagas disease: A review.
咪唑和苯并咪唑杂环在恰加斯病中的作用:综述
Eur J Med Chem. 2020 Nov 15;206:112692. doi: 10.1016/j.ejmech.2020.112692. Epub 2020 Aug 5.
4
QSAR without borders.无边界定量构效关系。
Chem Soc Rev. 2020 Jun 7;49(11):3525-3564. doi: 10.1039/d0cs00098a. Epub 2020 May 1.
5
Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.克鲁蛋白酶的拟肽乙烯基杂环抑制剂具有抗锥虫活性。
J Med Chem. 2020 Mar 26;63(6):3298-3316. doi: 10.1021/acs.jmedchem.9b02078. Epub 2020 Mar 17.
6
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review.寻找治疗恰加斯病、利什曼病和血吸虫病的药物:综述。
Int J Antimicrob Agents. 2020 Apr;55(4):105906. doi: 10.1016/j.ijantimicag.2020.105906. Epub 2020 Jan 25.
7
Structure-Based and Molecular Modeling Studies for the Discovery of Cyclic Imides as Reversible Cruzain Inhibitors With Potent Anti- Activity.基于结构和分子建模研究发现环状酰亚胺作为具有强效抗活性的可逆克鲁蛋白酶抑制剂。
Front Chem. 2019 Nov 25;7:798. doi: 10.3389/fchem.2019.00798. eCollection 2019.
8
Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.发现具有抗锥虫活性的强效、可逆和竞争性克氏锥虫抑制剂:一种基于结构的药物设计方法。
J Chem Inf Model. 2020 Feb 24;60(2):1028-1041. doi: 10.1021/acs.jcim.9b00802. Epub 2019 Dec 11.
9
Structure-Based Virtual Screening and In Vitro Evaluation of New Cruzain Inhibitors.基于结构的虚拟筛选和新型克氏锥虫抑制剂的体外评价。
Int J Mol Sci. 2019 Apr 9;20(7):1742. doi: 10.3390/ijms20071742.
10
QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery.基于定量构效关系的虚拟筛选:药物发现中的进展与应用
Front Pharmacol. 2018 Nov 13;9:1275. doi: 10.3389/fphar.2018.01275. eCollection 2018.